• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Summary of changes in the 2025 Canadian Urological Association-Canadian Urologic Oncology Group Guideline on metastatic castration-naive and castration-sensitive prostate cancer.2025年加拿大泌尿外科学会-加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌指南的变化总结
Can Urol Assoc J. 2025 May;19(5):E140-E141. doi: 10.5489/cuaj.9228.
2
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Summary of changes.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌 变更摘要
Can Urol Assoc J. 2022 Dec;16(12):389-391. doi: 10.5489/cuaj.8159.
3
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
4
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌全文
Can Urol Assoc J. 2022 Dec;16(12):E581-E589. doi: 10.5489/cuaj.8148.
5
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).2025年加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌（更新版）
Can Urol Assoc J. 2025 May;19(5):E142-E152. doi: 10.5489/cuaj.9240.
6
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2022年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2022 Nov;16(11):E506-E515. doi: 10.5489/cuaj.8161.
7
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2021年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
8
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2019年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136.
9
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?更新 - 2021年加拿大泌尿外科协会（CUA）-加拿大泌尿肿瘤学组（CUOG）去势抵抗性前列腺癌（CRPC）指南：自2019年以来有哪些变化？
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
10
Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.对于接受阿比特龙醋酸酯一线治疗的日本LATITUDE高危转移性去势敏感性前列腺癌患者，无进展生存期的有用预测指标。
Int J Urol. 2022 Mar;29(3):229-234. doi: 10.1111/iju.14754. Epub 2021 Dec 4.

本文引用的文献

1
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data.转移性激素敏感性前列腺癌患者的三联或双联疗法：一项纳入ARANOTE数据的更新网络荟萃分析
Eur Urol Focus. 2024 Dec 5. doi: 10.1016/j.euf.2024.11.004.
2
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.来自III期ARANOTE试验的达洛鲁胺联合雄激素剥夺疗法治疗转移性激素敏感性前列腺癌患者
J Clin Oncol. 2024 Dec 20;42(36):4271-4281. doi: 10.1200/JCO-24-01798. Epub 2024 Sep 16.
3
2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.2023年加拿大泌尿外科协会指南：前列腺癌的基因检测
Can Urol Assoc J. 2023 Oct;17(10):314-325. doi: 10.5489/cuaj.8588.
4
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.睾酮抑制联合恩扎卢胺与睾酮抑制联合标准抗雄激素治疗转移性激素敏感性前列腺癌（ENZAMET）：一项国际、开放标签、随机、III 期临床试验。
Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3.
5
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
6
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存 **注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
7
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
8
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.临床中遗传性前列腺癌的胚系基因检测：对基因检测、精准治疗和级联检测的影响。
Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.
9
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.跨疾病状态的前列腺癌前瞻性基因组分析揭示了可能影响临床决策的种系和体细胞改变。
JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
10
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.转移性前列腺癌男性患者的遗传性DNA修复基因突变
N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.

Summary of changes in the 2025 Canadian Urological Association-Canadian Urologic Oncology Group Guideline on metastatic castration-naive and castration-sensitive prostate cancer.

作者信息

So Alan I, Saad Fred

机构信息

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.

Division of Urology, Department of Surgery, Université de Montréal, Montreal, QC, Canada.

出版信息

Can Urol Assoc J. 2025 May;19(5):E140-E141. doi: 10.5489/cuaj.9228.

DOI:10.5489/cuaj.9228
PMID:40398387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12091045/
Abstract
摘要